Group 1 | Group 2 | ||||
---|---|---|---|---|---|
Measurement | Mean (95% CI) | n | Mean (95% CI) | n | p* |
Lung function tests | |||||
FVC (%) | 58 (44–72) | 20 | 69 (58–74) | 20 | 0.4 |
FEV 1/s (%) | 59 (46–72) | 20 | 69 (61–72) | 20 | 0.2 |
Respiratory muscle force | |||||
MIP (cmH2O) | 29 (20–39) | 21 | 48 (30– 65) | 20 | 0.07 |
MEP (cmH2O) | 40 (28–52) | 21 | 60 (42–78) | 20 | 0.07 |
SNP (cmH2O) | 24 (9–40) | 18 | 31 (21–41) | 18 | 0.1 |
PCF (l/min) | 240 (180–300) | 18 | 310 (250–370) | 20 | 0.1 |
Severity of hypoventilation symptoms | |||||
Dyspnoea | 4 (3–6) | 21 | 2 (1–3) | 20 | 0.05 |
Cough weakness | 3 (2–5) | 21 | 3 (1–4) | 20 | 0.4 |
Sleep disturbance | 5 (3–6) | 21 | 3 (2–3) | 20 | 0.05 |
Morning headaches | 2 (0–3) | 21 | 1 (0–2) | 20 | 0.7 |
Daytime sleepiness | 4 (3–6) | 21 | 4 (2–5) | 20 | 0.4 |
Thoracic movement (cm) | 2.9 (2.2–3.6) | 22 | 4.0 (3.4–4.8) | 20 | 0.01 |
Respiratory rate (breaths/min) | 21 (18–24) | 22 | 16 (14–18) | 20 | 0.005 |
Arterial blood-gas analysis | |||||
pCO2 (kPa) | 6.3 (5.6–6.9) | 17 | 5.3 (5.0–5.6) | 12 | 0.007 |
pO2 (kPa) | 9.8 (9.3–10.4) | 17 | 10.7 (9.4–12) | 12 | 0.4 |